Dossier
mRNA-based vaccine
Coverage of mRNA-based vaccine in the Nexus archive.
- Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial
Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial. The mRNA-based vaccine combined with Keytruda was shown to reduce melanoma recurrence in over 1,100 patients. These patients were those whose cancer had been surgically removed.